Abstract
Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have